Lymphoma

The first gluteal implant case has raised concern for risk of anaplastic large cell lymphoma in more than just textured breast implants.

Three-time cancer survivor and “Pink Hulk” one-woman show writer and performer, Valerie David, recalls the day she learned she had non-Hodgkin lymphoma.

A lymphoma expert discusses implant removal, reconstruction and the signs of anaplastic large cell lymphoma.

The Food and Drug Administration has requested that the manufacturer voluntarily recall certain breast implants and tissue expanders from the market to protect women from risks such as breast implant-associated anaplastic large cell lymphoma.

With the Food and Drug Administration’s approval of Ruxience, a biosimilar to Rituxan, patients with certain types of non-Hodgkin lymphoma and chronic lymphocytic leukemia may have improved access to a more affordable treatment option.

How an app gives a glimpse into the future for many patients with cancer and survivors who fear they won't make it to old age.

The Food and Drug Administration granted CLR 131, a targeted, molecular radiotherapy, a fast track designation.

A lymphoma expert discusses the side effect profile and follow-up data from the ECHELON-1 clinical trial.

Women who undergo a mastectomy have many options and concerns to consider when undergoing breast reconstruction. My choice was simple: I wanted to look as natural as possible, but I have since learned that I have textured implants.

When I was diagnosed with Hodgkin's lymphoma, I envisioned myself in a galaxy far, far away. Just like any well-trained Jedi, I fought back when insurance denied my claim for doctor-recommended treatment.

Here are three things I learned to avoid when recovering from cancer treatment.

The FDA has granted an accelerated approval to Polivy for use in combination with bendamustine and Rituxan for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma who have received at least two prior therapies.

Having hope in the now is really faith in the future.

The Food and Drug Administration has approved the combination regimen of Revlimid plus Rituxan for use in patients with previously-treated follicular lymphoma and marginal zone lymphoma.

The FDA has approved Jakafi, the first and only treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients aged 12 years and older.

From World Blood Cancer Day to today’s top performers fundraising for lifesaving research, here’s what’s making headlines in the cancer space this week.

In this episode, we spoke with a rare lymphoma survivor on how chimeric antigen receptor T-cell therapy saved her life.

In this episode of CURE® Talks Cancer, we spoke with an advocate who is raising awareness around the recent controversy surrounding a certain type of breast implant that is causing a rare type of lymphoma.

Only half of patients reported their blood cancer was detected while visiting a doctor after experiencing symptoms versus detection during a routine medical test or exam or while under the care of a doctor for another health condition.

Extraordinary Healer® Award finalist Angela Hammack, B.S.N., RN, OCN, discussed how she began running marathons to raise awareness – and $100,000 – for cancer.

Here are the top 5 CURE stories for March 2019.

How being treated for an allergy to cats and persistence finally led to my diagnoses of Hodgkin's lymphoma.

Productivity loss among parent caregivers associated with poor health-related quality of life in pediatric advanced stage Hodgkin lymphoma.

In order to help others, this survivor and author must "bare all" to get his message out.

Treating younger patients with low-risk diffuse large B-cell lymphoma (DLBCL) with two fewer front-line cycles of standard treatment greatly reduced toxicity without sacrificing effi­cacy.

The Food and Drug Administration granted a priority review to Revlimid (lenalidomide) plus Rituxan (rituximab) for the treatment of patients with previously treated follicular lymphoma and marginal zone lymphoma.

The Food and Drug Administration granted a priority review to polatuzumab vedotin in combination with bendamustine plus Rituxan (rituximab) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

While some high-risk patients with mantle cell lymphoma may benefit from aggressive initial therapy, a recent study found that this may not be necessary for others who could benefit from more targeted therapies.

Outwardly, you start to look like your old self again while inside you're still licking the wounds of your cancer battle.